Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

96 results found

Title
Status

 

CFI-400945-AML-201/TWT-202 - Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML

Open

CFI-400945-AML-201/TWT-202 - Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML

Go to Health Care Provider version

DiagnosisAcute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)Study StatusOpen
PhaseI/II
Age18 Years and older RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: CFI-400945 (oral) Arm 2A only: Azacitidine (IV)
Last Posted Update2024-04-09
ClinicalTrials.gov #NCT04730258
International Sponsor
Treadwell Therapeutics, Inc
Principal Investigators for Canadian Sites
Princess Margaret Cancer Centre
Centres
Medical contact

    CNS - Dr. Julie Bennett

     julie.bennett@sickkids.ca

     Sarcoma - Dr. Abha Gupta

     abha.gupta@uhn.ca

     Leukemia & Lymphoma - Dr. Dawn Maze

     dawn.maze@uhn.ca

Social worker/patient navigator contact

Please contact medical team for further information.

Clinical research contact

     CNS Trials - On Yee Jones

     onyee.jones@uhn.ca

     Sarcoma Trials - Hagit Peretz Soroka

     hagit.peretz@uhn.ca

     Leukemia & Lymphoma Trials - Deborah Sanfelice 

     deborah.Sanfelice@uhn.ca

 

 

Study Description

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

Inclusion Criteria
  • Patients must be >18 years of age
  • Patients must have a qualifying diagnosis of Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) that has come back or not responded to other treatment
  • Have acceptable laboratory screening results within certain limits
  • Be able to carry out light daily work with little/no restriction

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team

IGNYTE-ESO - Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Closed to enrollment

IGNYTE-ESO - Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Go to Health Care Provider version

DiagnosisAdvanced tumorsStudy StatusClosed to enrollment
PhaseII
Age10 Years and olderRandomisationNO
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationDrug: Letetresgene autoleucel (lete-cel, GSK3377794) letetresgene autoleucel will be administered. Drug: Fludarabine Fludarabine will be used as the lymphodepleting chemotherapy Drug: Cyclophosphamide Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Last Posted Update2024-04-09
ClinicalTrials.gov #NCT03967223
International Sponsor
GlaxoSmithKline
Principal Investigators for Canadian Sites
Maisonneuve-Rosemont Hospital
Centres
Medical contact
N/A
Social worker/patient navigator contact
N/A
Clinical research contact
N/A

 

 

Study Description

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumours.

Inclusion Criteria
  • Participant must be greater than or equal to 10 years of age on the day of signing informed consent.
  • Participant has a diagnosis of synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS)
  • Participant should be up and about 60% of their waking hours with minimal to no restrictions 
  • Participant must meet the lab and organ function requirements prior to starting study

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team

NIR-DT-301 - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Closed to enrollment

NIR-DT-301 - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Go to Health Care Provider version

DiagnosisDesmoid Tumor, Aggressive FibromatosisStudy StatusClosed to enrollment
PhaseIII
Age18 Years and olderRandomisationYES
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationDrug: Nirogacestat 150 mg by mouth, twice daily
Last Posted Update2024-04-09
ClinicalTrials.gov #NCT03785964
International Sponsor
SpringWorks Therapeutics, Inc.
Principal Investigators for Canadian Sites
Princess Margaret Cancer Centre
McGill University Health Centre
Centres
Medical contact

Sarcoma - Dr. Jonathan Noujaim 

     jonathan.noujaim.med@ssss.gouv.qc.ca

Sarcoma  -  Dr. Ramy Saleh    

 ramy.saleh@mcgill.ca

Social worker/patient navigator contact
N/A
Clinical research contact

Sarcoma - Mahafarin Maralani

     mahafarin.maralani@muhc.mcgill.ca

Medical contact

    CNS - Dr. Julie Bennett

     julie.bennett@sickkids.ca

     Sarcoma - Dr. Abha Gupta

     abha.gupta@uhn.ca

     Leukemia & Lymphoma - Dr. Dawn Maze

     dawn.maze@uhn.ca

Social worker/patient navigator contact

Please contact medical team for further information.

Clinical research contact

     CNS Trials - On Yee Jones

     onyee.jones@uhn.ca

     Sarcoma Trials - Hagit Peretz Soroka

     hagit.peretz@uhn.ca

     Leukemia & Lymphoma Trials - Deborah Sanfelice 

     deborah.Sanfelice@uhn.ca

 

 

Study Description

This research looks at how well a medicine called nirogacestat works in treating desmoid tumours or aggressive fibromatosis. At first, patients participating in the study are split into two groups randomly: one group gets nirogacestat, and the other group gets a placebo, which is a which is a substance that has no therapeutic effect and is indistinguishable from the actual drug. This part of the study is "double-blind," meaning neither the participants nor the researchers know who's getting the real medicine and who's getting the placebo. Later, when participants move to the next part of the study, called the "open-label phase," everyone gets nirogacestat. 

Inclusion Criteria
  • Participants must be 18 years or older
  • Must have confirmed Desmoid Tumor or Aggressive Fibromatosis that has progressed or not responded after at least one line of therapy 
  • Participants must be up and about at least 50% of their daily waking hours
  • Participants must meet organ function and lab criteria prior to starting on study
  • Participants must sign an informed consent and agree to the study assessments and requirements

Other inclusion and exclusion criteria may apply and will be discussed with you by your study team. 

SU2C-SARC032 - A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Closed to enrollment

SU2C-SARC032 - A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Go to Health Care Provider version

DiagnosisSoft Tissue SarcomaStudy StatusClosed to enrollment
PhaseII
Age≥ 12 yearsRandomisationYES
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationDrug: Pembrolizumab (KEYTRUDA®) Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm. Participants not on the treatment arm will receive standard of care radiotherapy followed by surgical resection.
Last Posted Update2024-04-09
ClinicalTrials.gov #NCT03092323
International Sponsor
Sarcoma Alliance for Research through Collaboration
Principal Investigators for Canadian Sites
McGill University Health Centre - Please email research contact
Centres
Medical contact

Sarcoma - Dr. Jonathan Noujaim 

     jonathan.noujaim.med@ssss.gouv.qc.ca

Sarcoma  -  Dr. Ramy Saleh    

 ramy.saleh@mcgill.ca

Social worker/patient navigator contact
N/A
Clinical research contact

Sarcoma - Mahafarin Maralani

     mahafarin.maralani@muhc.mcgill.ca

 

 

Study Description

This study is trying to find out if adding a new drug (pembrolizumab) to the standard treatment for soft tissue sarcoma, makes the treatment work better. Researchers will compare two groups: one group gets the standard treatment of radiation before surgery, and the other group gets pembrolizumab with radiation before surgery, plus more pembrolizumab after surgery for a year, to see which group does better.

Inclusion Criteria
  • Participant must be 12 years of age or older
  • Participant must have an applicable sarcoma diagnosis in their extremity (patients with skin cancer, carcinoma or low-risk prostate cancer may also be eligible)
  • Participant should be able to be up and about throughout the day with minimal restriction 
  • Must meet all lab and organ function requirements within 10 days of starting on study 
  • Participant or parent/caregiver must be willing to sign an informed consent and agree to the study requirements 
  • If participants are able to have children, they must agree to use an effective method of birth control while on study and for 120 days after the last dose of pembrolizumab. 

Other inclusion criteria and exclusion criteria apply and will be discussed with you by the study team 

CC-96191-AML-001 - A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Open

CC-96191-AML-001 - A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Go to Health Care Provider version

DiagnosisMyeloid LeukemiaStudy StatusOpen
PhaseI
Age18 Years and older RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationCC-96191 will be administered intravenously on a 28-day Cycle
Last Posted Update2024-04-09
ClinicalTrials.gov #NCT04789655
International Sponsor
Celgene
Principal Investigators for Canadian Sites
Princess Margaret Cancer Centre
Centres
Medical contact

    CNS - Dr. Julie Bennett

     julie.bennett@sickkids.ca

     Sarcoma - Dr. Abha Gupta

     abha.gupta@uhn.ca

     Leukemia & Lymphoma - Dr. Dawn Maze

     dawn.maze@uhn.ca

Social worker/patient navigator contact

Please contact medical team for further information.

Clinical research contact

     CNS Trials - On Yee Jones

     onyee.jones@uhn.ca

     Sarcoma Trials - Hagit Peretz Soroka

     hagit.peretz@uhn.ca

     Leukemia & Lymphoma Trials - Deborah Sanfelice 

     deborah.Sanfelice@uhn.ca

 

 

Study Description

This study will explore the safety, tolerability and efficacy of the biologic CC-96191 in acute myeloid leukemia (AML) that has come back or not responded to previous treatment. 

Inclusion Criteria
  • Patient must be 18 years or older
  • Patient must have AML that has come back (relapsed) or not responded to previous treatment
  • Patient must be willing to sign a consent form
  • Females and males must practice true abstinence or agree to approved contraceptive methods throughout the study, and during the safety follow-up period.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

ACNS1721 - A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Closed to enrollment

ACNS1721 - A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Go to Health Care Provider version

DiagnosisAnaplastic Astrocytoma, Glioblastoma, Malignant GliomaStudy StatusClosed to enrollment
PhaseII
Age3 Years to 25 YearsRandomisationNO
Line of treatmentFirst line treatment
Routes of Treatment AdministrationRadiation Therapy (Undergo radiation therapy) Drug: Temozolomide (Given by mouth) Drug: Veliparib (Given by mouth)
Last Posted Update2024-03-19
ClinicalTrials.gov #NCT03581292
International Sponsor
National Cancer Institute (NCI)
Principal Investigators for Canadian Sites
Hamilton Health Sciences Centre, McMaster University - Dr. Uma H. Athale
Centres
Medical contact
Dr. Carol Portwine
 
Social worker/patient navigator contact
Jane Cassano 
 
Clinical research contact
Sabrina Millson
 
 

 

 

Study Description

This study is aimed at improving the outcome for children with High Grade Glioma (HGG). Temozolomide, a medication taken by mouth, has been shown to improve survival in adults with glioblastoma, when taken during and after radiation. In this study, patients with a HGG that has specific molecular features (wild-type for H3-K27, IDH and BRAF) will receive experimental therapy of veliparib (given by mouth) during radiation therapy, followed by veliparib in combination with temozolomide.

This study will test whether this combination therapy may improve survival in children with newly diagnosed HGG that are wild-type for H3-K27, IDH and BRAF. Patients with IDH mutant glioma are also eligible. The outcomes of patients on this study will be compared to other patients with clinically and molecularly similar HGG treated with temozolomide alone.

(Retrieved from: https://www.childrensoncologygroup.org/acns1721)

Inclusion Criteria
  • Patients must be at least 3 years old and less than 22 years of age. Patients less than 25 years old may be eligible to enroll if they have a specific type of high grade glioma
  • Patients must have newly diagnosed High Grade Glioma, that does not include brainstem or spinal cord tumors, or disease that has spread to other parts of the body (metastatic disease)
  • Patients must agree to the study activities outlined in the consent forms; including MRI's, blood tests, biopsies etc - as they apply
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours
  • If the patient has a seizure disorder, they may be enrolled if the seizures are well-controlled
  • A written consent form must be signed by the patients and/or their parents/legal guardians

Other inclusion and exclusion criteria may apply and will be discussed with you by the study doctor.

NMTRC012 - A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Open

NMTRC012 - A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Go to Health Care Provider version

DiagnosisNeuroblastomaStudy StatusOpen
PhaseII
AgeChild, Adult - (up to 22 Years )RandomisationYES
Line of treatmentFirst line treatment
Routes of Treatment AdministrationDFMO - oral Other drugs are given as usually administered for neuroblastoma therapy
Last Posted Update2024-03-19
ClinicalTrials.gov #NCT02559778
International Sponsor
Giselle Sholler
Principal Investigators for Canadian Sites
CHU Ste-Justine – Dr. Pierre Teira
CHU Quebec - Dr Bruno Michon
CHU Sherbrooke - Dr. Josée Brossard
Centres
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Dr. Josee Brossard 
Social worker/patient navigator contact
Please Contact Site Directly
 
Clinical research contact
Please Contact Site Directly 
 

 

 

Study Description

This study is to assess the effectiveness of molecular targeted therapy (four different possible medications) in addition to standard therapy for patients with a new diagnosis of high-risk neuroblastoma. The study also looks at the side effects associated with these medications.

The study also tests the effects of a drug called DFMO when added to the immunotherapy given as post-consolidation treatment.

Inclusion Criteria
  • Age 1 to 22 years
  • New diagnosis of high risk neuroblastoma
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

BCC018 - A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Open

BCC018 - A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Go to Health Care Provider version

DiagnosisHigh-risk NeuroblastomaStudy StatusOpen
PhaseII
Age12 Months to 21 YearsRandomisationNO
Line of treatmentFirst line treatment
Routes of Treatment AdministrationDrug: Naxitamab (Intravenous (IV)) Additionally for patients with ALK aberration: Drug: Ceritinib (Oral)
Last Posted Update2024-03-19
ClinicalTrials.gov #NCT05489887
International Sponsor
Wake Forest University Health Sciences
Principal Investigators for Canadian Sites
CHU Quebec - Dr.Bruno Michon
CHU Ste Justine - Dr. Pierre Teira
Centres
Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 

 

 

Study Description

This is a Phase 2 trial for newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of combining the drug naxitamab with standard induction therapy. Initially, there will be 5 cycles of standard chemotherapy with Naxitamab on days 1, 3 and 5 of each cycle. Patients with an ALK mutation or amplification will have the drug ceritinib added to their treatment regimen as soon as results are available. 

Inclusion Criteria
  • Subjects must have a diagnosis of neuroblastoma or ganglioneuroblastoma that meets criteria
  • Subjects must be age ≤ 21 years at initial diagnosis
  • Subjects must be >12 months of age at enrollment
  • Subject's bloodwork must be within acceptable study ranges
  • Pregnant subjects are not eligible for this study, a negative serum pregnancy test is required for female participants of childbearing potential
  • Both male and female study subjects who have reached puberty must be willing to use a highly effective contraceptive method, these methods will be discussed with you by the study team
  • All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines.
  • Subjects enrolled on study must complete all required assessments